Clinical trial · Interventional
Usefulness of the Artery First Approach in Pancreatic Cancer Surgery
A Prospective Randomized Study of the Usefulness of the Artery First Approach in Pancreatic Cancer With Pancreaticoduodenectomy
NCT04136522CI-TRIAL-00059755unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is aimed to evaluate difference of the 2 year recurrence free survival after pancreaticoduodenectomy for pancreatic cancer between artery-first approach and conventional procedure groups.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Margin, Tumor-Free | — | UNRESOLVED | — |
| Pancreatic Cancer, Adult | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.85 |
| Recurrence Tumor | — | UNRESOLVED | — |
| Surgery Site Fistula | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional pancreaticoduodenectomy | Procedure | — | UNRESOLVED |
| total mesopancreas excision including superior mesenteric artery first approach | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- conventional
- description
- The patients who included this group will undergo conventional pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). We will identify and isolate superior mesenteric vein (SMV) before pancreatic resection. The surgeon will dissect tissue around superior mesenteric artery (SMA) and uncinate process of pancreas along the SMA.
- interventionNames
- Procedure: conventional pancreaticoduodenectomy
- type
- EXPERIMENTAL
- label
- total mesopancreas excision with arterial first approach
- description
- The patients who included this group will undergo PD or PPPD including total pancreatic mesopancreas excision and superior mesenteric artery approach. Before pancreatic transection, the surgeon will isolate superior mesenteric vein (SMV) and superior mesenteric artery (SMA). And the surgeon will dissect nerve plexus and lymph node around SMA. inferior pancreaticoduodenal artery (IPDA) and first jejunal artery will be identified and the surgeon will ligate according to surgical margin. Anastomosis will be performed as usual manners.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Resectable pancreatic head cancer * No systemic metastasis * Age \> 20 years * The patients who understand informed consent and is able to agree with study Exclusion Criteria: * The patients who have systemic metastasis * The patients who need neoadjuvant therapy in borderline resectable and locally advanced pancreatic cancer * Those with active or uncontrolled infections * Those with severe psychiatric / neurological disorders * Alcohol or other drug addicts * Patients with moderate or severe comorbidities who are thought to have an impact on quality of life or nutritional status (cirrhosis, chronic kidney failure, heart failure, etc.)
References
Publications (0)
Data not yet available
No reference posted for this study.